title: The effect of fluoride on bone histology in postmenopausal osteoporosis depends on adequate fluoride absorption and retention.
abstract: Forty-one women with idiopathic postmenopausal osteoporosis have been followed for 2 years after initiation of sodium fluoride at 40-50 mg/day, given together with a daily calcium supplement of 1 gram and vitamin D2, at 50,000 IU weekly. Histological and histomorphometric analyses were done on bone biopsies taken prior to and after 1 year of treatment (mean 1.25 +/- 0.35 years). Thirty patients (74%) developed the histological fluoride effect of hyperosteoidosis, while the remaining 11 patients (26%) had no change from pretreatment biopsies. Hyperosteoidosis was based on increased values for osteoid volume and/or thickened osteoid with greater than 3 lamellar bands. Based on previously reported findings, this histological evidence of hypersoteoidosis within 12-18 months of initiation of therapy provides a useful predictor of ultimate satisfactory fluoride response in terms of bone mineral accretion. No increases in bone mass (measured by neutron activation analysis) were observed at the time of the posttreatment biopsy but, according to this previous work, increases are anticipated over a further 2-3 years of treatment. Factors affecting the development of hyperosteoidosis were analyzed. Hyperosteoidosis was associated with a significantly higher dose of sodium fluoride and a significantly higher level of bone fluoride retention but without significant increase in fasting serum fluoride. Results suggest that fluoride retention depends not only on fluoride dose but also on body size, renal function, and intestinal absorptions of calcium and fluoride. There were no differences in the initial investigations between patients with and without hyperosteoidosis, with respect to age, years of postmenopause, estrogen use, initial biochemistry, or initial bone histology.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of Toronto, St. Michael's Hospital, Canada.
authors.forename: F H
authors.initials: FH
authors.lastname: Budden
authors.forename: T A
authors.initials: TA
authors.lastname: Bayley
authors.forename: J E
authors.initials: JE
authors.lastname: Harrison
authors.forename: R G
authors.initials: RG
authors.lastname: Josse
authors.forename: T M
authors.initials: TM
authors.lastname: Murray
authors.forename: W C
authors.initials: WC
authors.lastname: Sturtridge
authors.forename: R
authors.initials: R
authors.lastname: Kandel
authors.forename: R
authors.initials: R
authors.lastname: Vieth
authors.forename: A L
authors.initials: AL
authors.lastname: Strauss
authors.forename: S
authors.initials: S
authors.lastname: Goodwin
mesh_terms: D001706:Biopsy; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008593:Menopause; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D012969:Sodium Fluoride / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D012969:Sodium Fluoride